Kazuhiro Nishikawa1, Akira Tsuburaya2, Takaki Yoshikawa3, Masazumi Takahashi4, Kazuaki Tanabe5, Kensei Yamaguchi6, Shigefumi Yoshino7, Tsutomu Namikawa8, Toru Aoyama3, Yasushi Rino9, Junji Kawada10, Akihito Tsuji11, Koichi Taira12, Yutaka Kimura13, Yasuhiro Kodera14, Yoshinori Hirashima15, Hiroshi Yabusaki16, Naoki Hirabayashi17, Kazumasa Fujitani10, Yumi Miyashita18, Satoshi Morita19, Junichi Sakamoto20. 1. Department of Surgery, Osaka National Hospital, 2-1-14 Houenzaka, Chuo-ku, Osaka, 540-0006, Japan. kazuno1@onh.go.jp. 2. Department of Surgery, Tsuboi Cancer Center Hospital, Koriyama, Japan. 3. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan. 4. Department of Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Japan. 5. Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan. 6. Division of Gastroenterology, Saitama Cancer Center, Kita-Adachi-Gun, Japan. 7. Oncology Center, Yamaguchi University Hospital, Ube, Japan. 8. Department of Surgery I, Kochi Medical School, Nankoku, Japan. 9. Department of Surgery, Yokohama City University, Yokohama, Japan. 10. Department of Surgery, Osaka General Medical Center, Osaka, Japan. 11. Department of Clinical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan. 12. Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan. 13. Department of Surgery, Faculty of Medicine, Kindai University, Osakasayama, Japan. 14. Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. 15. Department of Medical Oncology and Hematology, Faculty of Medicine, Oita University, Oita, Japan. 16. Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan. 17. Department of Surgery, Hiroshima City Asa Hospital, Hiroshima, Japan. 18. Epidemiological and Clinical Research Information Network (ECRIN), Okazaki, Japan. 19. Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 20. Tokai Central Hospital, Kakamigahara, Japan.
Abstract
BACKGROUNDS: In Japan, standard regimens for advanced gastric cancer (AGC) include S-1 chemotherapy. The standard treatment for early relapse after adjuvant chemotherapy with fluoropyrimidine alone is platinum-based chemotherapy, while the standard treatment for early relapse after adjuvant chemotherapy with fluoropyrimidine plus platinum is second-line chemotherapy. To evaluate the efficacy and safety of capecitabine plus cisplatin (XP) treatment for AGC patients who relapse within 6 months after S-1-based therapy, we conducted a multicenter phase II trial (NCT01412294). METHODS:HER2-negative gastric cancer patients treated withadjuvant chemotherapy including S-1 for more than 12 weeks and relapsed within 6 months were treated with capecitabine 1000 mg/m2 bid for 14 days plus cisplatin 80 mg/m2 on day 1 of a 3-week cycle. The primary endpoint was PFS; secondary endpoints were OS, time to treatment failure, overall response rate (ORR) and safety. RESULTS:Forty patients (median age 64) were enrolled; of those, 37 (92.5%) receivedadjuvant S-1 monotherapy. Median PFS was 4.4 months (95% CI 3.6-5.1), which was longer than the 2-month protocol-specified threshold (p < 0.001). Median OS was 13.7 months (95% CI 9.0-17.7) and ORR was 8/30 (26.7%) (95% CI 14.2-44.4). Most common grade ≥ 3 adverse events were neutropenia (23%), anemia (18%), elevated serum creatinine (18%), fatigue (13%), diarrhea (7.5%), and anorexia (7.5%). CONCLUSIONS:XP was safe and effective in patients with early relapse after S-1 adjuvant chemotherapy for curatively resected gastric cancers. XP may be a good option for the treatment of patients after early failure after adjuvant S-1. TRIAL REGISTRATION: NCT01412294.
RCT Entities:
BACKGROUNDS: In Japan, standard regimens for advanced gastric cancer (AGC) include S-1 chemotherapy. The standard treatment for early relapse after adjuvant chemotherapy with fluoropyrimidine alone is platinum-based chemotherapy, while the standard treatment for early relapse after adjuvant chemotherapy with fluoropyrimidine plus platinum is second-line chemotherapy. To evaluate the efficacy and safety of capecitabine plus cisplatin (XP) treatment for AGC patients who relapse within 6 months after S-1-based therapy, we conducted a multicenter phase II trial (NCT01412294). METHODS:HER2-negative gastric cancerpatients treated with adjuvant chemotherapy including S-1 for more than 12 weeks and relapsed within 6 months were treated with capecitabine 1000 mg/m2 bid for 14 days plus cisplatin 80 mg/m2 on day 1 of a 3-week cycle. The primary endpoint was PFS; secondary endpoints were OS, time to treatment failure, overall response rate (ORR) and safety. RESULTS: Forty patients (median age 64) were enrolled; of those, 37 (92.5%) received adjuvant S-1 monotherapy. Median PFS was 4.4 months (95% CI 3.6-5.1), which was longer than the 2-month protocol-specified threshold (p < 0.001). Median OS was 13.7 months (95% CI 9.0-17.7) and ORR was 8/30 (26.7%) (95% CI 14.2-44.4). Most common grade ≥ 3 adverse events were neutropenia (23%), anemia (18%), elevated serum creatinine (18%), fatigue (13%), diarrhea (7.5%), and anorexia (7.5%). CONCLUSIONS: XP was safe and effective in patients with early relapse after S-1 adjuvant chemotherapy for curatively resected gastric cancers. XP may be a good option for the treatment of patients after early failure after adjuvant S-1. TRIAL REGISTRATION: NCT01412294.
Entities:
Keywords:
Advanced gastric cancer; Capecitabine plus cisplatin (XP); Early relapse; Fluoropyrimidine switching; S-1 adjuvant therapy
Authors: Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: M Miwa; M Ura; M Nishida; N Sawada; T Ishikawa; K Mori; N Shimma; I Umeda; H Ishitsuka Journal: Eur J Cancer Date: 1998-07 Impact factor: 9.162
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: H J Kang; H M Chang; T W Kim; M-H Ryu; H J Sohn; J H Yook; S T Oh; B S Kim; J-S Lee; Y-K Kang Journal: Br J Cancer Date: 2005-01-31 Impact factor: 7.640